Loading clinical trials...
Loading clinical trials...
A Phase 2a Study to Evaluate the Effects of DaxibotulinumtoxinA for Injection on the Treatment of Dynamic Forehead Lines and Glabellar Lines
Conditions
Interventions
DAXXIFY
Locations
1
United States
Revance
Nashville, Tennessee, United States
Start Date
April 8, 2024
Primary Completion Date
December 12, 2024
Completion Date
February 12, 2025
Last Updated
April 4, 2025
NCT05481931
NCT05146999
NCT05148000
NCT05277337
NCT04249583
NCT05217355
Lead Sponsor
Revance Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions